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Background/aim: The aberrant upregulation of Forkhead box protein M1 (FOXM1) plays a fundamental role in cancer initiation by
perturbing stem cell differentiation. This study aims to investigate the role of FOXM1 in epigenetic modification and gene expression
of target genes in primary human oral keratinocytes, squamous cell carcinoma cell lines, and head and neck squamous cell carcinoma
(HNSCC) tissue biopsies.
Materials and methods: A genome-wide promoter methylation microarray was used to compare HNSCC cell line (n = 8), primary
human oral keratinocytes (NOK; n = 8) transduced with FOXM1 and EGFP, and HNSCC tissue biopsies (n = 3). Seventeen Foxm1Binduced differentially methylated genes were shortlisted. An absolute quantitative polymerase chain reaction was used to validate the
differential promoter DNA methylation of each candidate gene induced by FOXM1. These results were compared with the methylation
status and altered gene expressions of candidate genes in a panel of genomic DNA and messenger RNA (mRNA) samples previously
extracted from HNSCC tissue biopsies.
Results: The results were consistent with our hypothesis, showing that aberrant upregulation of FOXM1 expression in in vitro primary
NOK induces a global hypomethylation pattern similar to the HNSCC cell line and has an inverse correlation with in vivo mRNA
expression levels of HNSCC tissue biopsy.
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Conclusion: Such epigenetic changes have tremendous clinical potential as biomarkers for early cancer detection and therapeutic
interventions.
Key words: Forkhead box protein M1, epigenetic modifications, gene expression
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1. Introduction
1.1. Head and neck squamous cell carcinoma
Cancers in the head and neck region are mostly referred
to as head and neck squamous cell carcinoma (HNSCC).
HNSCC is the fifth most common cancer and the sixth
most common cause of mortality in the world. In 2007,
according to the National Cancer Institute Surveillance
Epidemiology and End Result cancer statistic review,
34,360 individuals were predicted to be diagnosed with
HNSCC (http://seer.cancer.gov/). This has raised severe
health concerns in the public all over the world.
There are various risk factors that are associated with
HNSCC. These factors encompass environmental factors
as well as personal lifestyles. Heavy alcohol consumption,
smoking tobacco, and chewing of betel quid with tobacco
are the established risk factors (1). Other predisposing
factors include dietary factors such as consumption of
* Correspondence: ayesha_khan23@live.com
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processed meats and red meat; lack of iron and essential
vitamins A, C, and E; exposure to UV light; and viral strains,
e.g., human papilloma virus (HPV), herpes simplex, and
the Epstein–Barr virus. These risk factors cause cancer by
bringing about epigenetic changes and genetic mutations.
Forkhead box protein M1 (FOXM1) is upregulated in a
majority of human cancers (2,3). It has been established
that FOXM1 is upregulated early in human squamous cell
carcinoma (4). Recently, FOXM1’s role in the initiation
of cancer by perturbing stem cell differentiation was
identified (5). Abnormal epigenetic modification such as
DNA methylation and demethylation is implicated in the
pathogenesis of solid tumors. These epigenetic changes
occur early during cancer stem cell initiation (6). The link
between epigenetic abnormalities and cancer evolution
is becoming clearer day by day. Research in the field of
head and neck cancers has shown significant advancement
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of the cell cycle even with the presence of damaged DNA,
and all of these events lead to genomic instability that
occurs due to loss of heterozygosity and chromosomal
number abnormality. In normal cells the tumor suppressor
genes are unmethylated and hence they are normally
transcribed and can perform their functions. Promoter
DNA methylation induces the loss of expression of tumor
suppressor genes, predisposing transformation of normal
cells into oncogenesis.
The other epigenetic mechanism is posttranslational
modification of amino acids in histone proteins.
Histones are proteins around which DNA wraps itself for
compaction. Histone modification appears to work by
maintaining and establishing the gene activity states as it
controls DNA accessibility. DNA is highly accessible when
histone H3 is methylated (H3K4me) and histone H4 is
hyperacetylated (H4K16Ac), whereas DNA is inaccessible
when histone 3 is methylated on lysine residue 27. The
H2A family of histone proteins plays a major role in
chromatin reprogramming; damage to this family changes
its functions and results in genomic instability and cellular
proliferation.
Any dysregulation in the abovementioned chief
epigenetic mechanisms can lead to numerous diseases like
cancer, autoimmune diseases, and neurological disorders
(9). Epigenetic changes are reversible and precede genetic
expression; therefore, they are thought to be an earlier
mechanism, with an edge over genetics. Epigenetic changes
have tremendous potential for the discovery of early cancer
biomarkers, essential in screening, diagnosis, prevention,
and treatment. For example, cancer can be prevented or
treated by reversing cancer-specific epigenetic changes
before irreversible mutations take place. Figure 1 illustrates
a common alteration in cancer cells: hypermethylation of
a tumor’s suppressor genes suppresses its transcription,
leading to loss of its normal cellular functions.
1.3. Forkhead box M1 transcriptional factor
FOXM1 (previously called HFH-11B, TRIDENT, WIN,
MPP2, and FOXM1b) is a protein that is encoded by the
FOXM1 gene in humans. This protein is a member of
the FOX family of transcription factors, which includes
a minimum of 50 unique FOX genes. FOXM1 is present
in 3 isoforms: FOXM1A/isoform1, FOXM1B/isoform3,
and FOXM1C/isoform2. All 3 isoforms can bind to DNA,
but only FOXM1B and FOXM1C act as transactivators
and hence can activate their target genes by binding to
5’-A(C/T)AAA(C/T)AA-3’ (3). The cellular localization and
regulation of FOXM1 is determined by posttranslational
modification such as phosphorylation of FOXM1.
FOXM1 protein is highly expressed in actively dividing
cells (17), whereas its levels are hardly detectable in
terminally differentiated cells (18). This protein plays a
key role in cell proliferation, cell growth, development,
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in the last few decades. Detection of HNSCC at an early
stage can increase survival by up to 80%, hence suggesting
that the early detection of stable markers such as DNA
methylation markers can provide immense assistance in
the diagnosis, treatment, and prediction of recurrence of
HNSCC.
1.2. Epigenetics
Epigenetics refers to heritable and stable changes in gene
expression without alteration in primary DNA sequences.
These changes are brought about by different epigenetic
mechanisms such as DNA methylation or methylation,
phosphorylation, or acetylation of histone proteins around
which the DNA wound itself to form chromatin. Epigenetic
regulation controls the cellular RNA expression patterns.
Epigenetics is involved in multiple processes such as gene
silencing, X chromosome inactivation, paramutation,
imprinting, the progress of carcinogenesis, and embryonic
development (7,8). Any dysregulation in epigenetic
mechanisms may lead to various human diseases, including
autoimmune diseases, cancer, and neurological disorders
(9). During cancer there is uncontrolled cell growth as cells
escape the normal physiological regulation of proliferation,
differentiation, and apoptosis. This takes place as a result
of the silencing of tumor suppressor genes or abnormal
activation of oncogenes. It has been established recently
that there are factors other than genetic abnormalities,
such as DNA sequence mutation and genomic instability,
that lead to cancer predisposition. Here epigenetics comes
into play. Research in this new field of science has shown
that the early epigenetic alterations are a prerequisite to
oncogenic genetic mutations that lead to cancer.
Of the various epigenetic mechanisms, DNA
methylation has been intensely investigated. It involves
the addition of a methyl group to the 5 position of the
cytosine pyrimidine ring. During cell proliferation
the DNA methylation pattern is maintained by DNA
methyltransferase enzymes (DNMT1, DNMT3a, and
DNMT3b) (10,11). DNA methylation plays a major role
in normal cellular differentiation and development. Stable
change in the methylation status of DNA can alter the gene
expression so that the cells have the ability to retain their
cellular pattern. Aberrant DNA methylation is associated
with malignancies and can occur in 2 forms: global DNA
hypomethylation and promoter DNA hypermethylation
(12–14). DNA hypomethylation is associated with
earlier stages of cancer. It can result in the reactivation
of various cancer- and growth-related genes as well as
chromosomal instability and genetic mutations, whereas
hypermethylation in cancer cells occurs in the promoter
regions of CpG islands (15,16) and results in the silencing
of tumor suppressor genes. The loss of function of tumor
suppressor genes leads to aberrant cell proliferation, lack
of DNA repair, apoptosis evasion, and the continuation
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Figure 1. DNA methylation in gene promoter region leads to repression of gene
expression.
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differentiation, and longevity. Cells lacking the FOXM1
protein show multiple defects, such as chromosomal
missegregation, polyploidy, an abnormal number
of chromosomes, defects in cytokinesis, and DNA
fragmentation. Hence, this suggests a fundamental role
for FOXM1 in DNA repair (19) as well as maintaining
genomic stability (2).
During embryogenesis FOXM1 expression is
induced in a number of tissues, as it plays a vital role in
the development of lungs, heart, blood vessels, and the
liver. In adult tissues its levels are greatly decreased, but
during organ injury and numerous cancers its expression
level is high (20). During the cell cycle FOXM1 levels are
found to be highest in the S phase and the G2/M phase
(3,17). FOXM1 can regulate the expression of multiple
cell cycle genes that control the G1/S transition phase,
S phase and M phase progression, and G2/M phase and
chromosomal segregation. FOXM1 itself is regulated by
cell cycle-promoting factors such as cyclin B and cyclin D
as well as antiproliferation signals that inhibit cell death,
differentiation, and cell cycle arrest (3). Other than cell
cycle transition, FOXM1 also plays important roles in DNA
damage repair (19), apoptosis (21), tissue regeneration
(22), angiogenesis (23), and metastasis (24).
1.4. FOXM1 role in human tumorigenesis
In addition to its key functions in the cell cycle and damaged
DNA repair, FOXM1 plays a pivotal role in oncogenesis.
FOXM1 is known as a human protooncogene. The first
evidence of a link between FOXM1 and cancer was
established in 2002, when it was found that in basal cell
carcinoma there is abnormal upregulation of FOXM1 (25).
Subsequent studies and microarray analyses have shown
that FOXM1 is overexpressed in a number of human
cancers. Furthermore, it has been established that during
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head and neck cancer FOXM1 expression is upregulated
during the early stages (4). Epithelial stem cells having
features like self-renewal, high migration capacity, drug
resistance, and high clonogenic potential are susceptible
to oncogenic selection and are thought to have a role in
the development and maintenance of the majority of
tumors. Studies have shown that FOXM1 plays a major
role in the regulation of adult epithelial stem cell renewal
and differentiation. Recent evidence supports the notion
that aberrant upregulation of FOXM1 expression in
undifferentiated human keratinocyte stem cells possessing
high clonogenic potential leads to a disturbance of epithelial
differentiation, leading to formation of hyperproliferative
“precancer” stem cells (5). This finding indicates that
abnormal upregulation of FOXM1 in normal stem cells
leads towards a multistep oncogenic evolutionary pathway.
The role of FOXM1 is not only limited to the initiation
of cancer; it also plays an important role in all stages of
tumorigenesis, from early predisposition and tumor
initiation (5) to cancer progression (4,26) and metastasis
(3). There are a number of carcinogenic and environmental
factors that activate FOXM1, resulting in uncontrolled
cell proliferation and malignant transformation: for
example, nicotine in tobacco (4), oxidative stress (27,28),
UV light (29), and ionizing irradiation (19). These factors
are reported to aberrantly increase FOXM1 expression
levels, which induces genomic instability and epigenetic
modification by activating downstream targets HELLS
and CEP55 protein. HELLS is a helicase required in DNA
strand separation, repair, replication, transcription, and
epigenetic modification such as DNA methylation. CEP55
is a mitotic phosphoprotein required in cytokinesis (30).
It has also been found that the gene locus of FOXM1
(12p13.3) is amplified in HNSCC. All these findings
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the gene of interest. Those cells that were unable to be
infected by virus were incapable of surviving the antibiotic
selection, while the remaining transduced cells were
cultured for viral production. A viral supernatant was
obtained and was used to transfect the target primary
human oral keratinocytes with FOXM1B and EGFP.
Retroviral supernatant and transduction procedures were
performed using our established protocols (4,5,29). Equal
levels of EGFP and FOXM1B expression were achieved
by serial retroviral supernatant titration experiment and
subsequently EGFP plasmid copy numbers were confirmed
by quantitative polymerase chain reaction (qPCR) using
genomic DNA extracted from transduced cells according
to our previously established method (29). The levels of
ectopic FOXM1 expression in the primary keratinocytes
were titrated to replicate levels found in cancer cells
as reported previously (4,5,29). Transduced cells were
cultured for 3–5 days to allow transgene expression prior
to experiment.
2.3. Statistical analysis
Statistical analysis was performed with Microsoft Excel
using the Student t-test (2-tailed). P < 0.05 was considered
to be statistically significant.
2.4. Ethical approval
The human tissues used in this study were approved by
Barts and the London NHS Trust; School of Medicine and
Dentistry, Queen Mary University of London; and the UK
National Research Ethics Committee.
2.5. Isolation of methylated genomic DNA
2.5.1. Fragmentation of gDNA
The samples used were DNA from normal oral keratinocytes
treated with EGFP, cells infected by FOXM1B, and the
HNSCC cell line (SCC15). This genomic DNA was
fragmented by treating it with an enzyme according to
the manufacturer’s protocol. The kit used was the Methyl
Collector Ultra (catalogue no. 55005) provided by Active
Motif Europe, Belgium.
2.5.2. Enriching methylated gDNA
The following protocol was used to enrich gDNA: a
complete binding buffer was prepared, and a high-salt and
a low-salt binding buffer were both produced by using
reagents supplied in the kit (Table 1).
Next, 10 µL of magnetic beads was added to the
required number of PCR tubes for the reaction and
components shown in Table 2 were added to the tubes to
complete the binding reaction.
The mixture was shaken and incubated for 1 h at 4
°C on a rotisserie shaker. The tubes were then placed on
a magnetic stand so that the beads moved to one side
and the supernatant that contained the unbound fraction
was removed. To resuspend the beads, they were washed
with 200 µL of binding buffer and the supernatant was
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suggest that aberrant upregulation of FOXM1 expression
results in oncogenic genomic instability and enhanced
cellular proliferation leading to the development of cancer.
1.5. FOXM1, epigenetics, and HNSCC
Exposure to the various risk factors (e.g., UV light, tobacco,
and ionizing radiations) associated with cancer may result
in aberrant overexpression of oncogene FOXM1. It is
also known that the loss of p53 function, c-MYC, RAS,
and p16/Rb pathway inactivation in cancer cells lead to
constitutive upregulation of FOXM1 (5). FOXM1 is known
as a driver mutation, which acts during the early stages of
oncogenesis by tumor initiation and predisposition (5).
Epigenetic changes occur early in the development of
cancer, followed by genetic mutations. FOXM1 initiates
cancer by uncontrolled expansion of stem cells and by
suppressing their differentiation (5). Aberrant expression
of FOXM1 leads to genomic instability and epigenetic
reprogramming by activating downstream targets CEP55
and DNMT1. CEP55 causes mitotic instability (4,31),
and deregulation of HELLS may lead to altered genomic
methylation due to downregulation of DNMT1 and
chromatin remodeling (4). This all suggests that abnormal
upregulation of FOXM1 brings epigenetic modifications
in conjunction with genomic instability, which causes
development of a heterogeneous population of abnormal
cells that are more likely to acquire properties that lead to
the development of cancer.
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2. Materials and methods
2.1. Patient nucleic acid samples
The use of human tissue in this study was approved by
Barts and the London NHS Trust; the School of Medicine
and Dentistry, Queen Mary University of London; and
the UK National Research Ethics Committee. All clinical
samples, which were additional to diagnosis, were collected
according to local ethics committee-approved protocols
and written informed patient consent was obtained from
all participants.
2.2. Cell culture and viral transduction
The primary normal human oral keratinocytes (OK355,
HOKG, OK113, NOK, NOK1, NOK3, NOK16, and
NOK376) used in this study were donated by healthy,
disease-free individuals undergoing wisdom tooth
extraction and were cultured as previously described
(4,29). Oral SCC cell line SCC15 (32) is a well-established
cell line cultured as described earlier (4,5,29).
In this experiment human primary oral keratinocytes
were grown and subsequently transduced by the gene of
interest. We used the FOXM1B human protooncogene
and EGFP (an inert enhanced green fluorescent
protein) as controls. In order to make infectious viral
particles, retroviral packaging cells (Phoenix A) were
first transduced with a retroviral DNA plasmid carrying
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Table 1. Buffer conditions.
High-salt binding conditions

Low-salt binding conditions

Reagent

One reaction

Reagent

One reaction

Binding buffer AM7

100 µL

Binding buffer AM12

100 µL

Protease Inhibitor cocktail

0.5 µL

Protease Inhibitor cocktail

0.5 µL

Total volume

100.5 µL

Total volume

100.5 µL

Table 2. Reagents used.
One reaction

Magnetic beads

10 µL
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Reagents
Complete binding buffer (high or low salt)

70 µL

Fragmented genomic DNA

From 1 ng to 1 µg (in a final volume of 10 µL)

His-MBD2/MBD3L1 protein complex

10 µL

Total volume

100 µL
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removed. To recover the methylated DNA fragments from
the beads they were resuspended in 100 µL of complete
elusion buffer.
Elusion buffer for each reaction consisted of 2 µL of
proteinase K and 98 µL of elusion buffer AM1. Next, it was
incubated for 30 min at 50 °C, inverted every 10 min so
that the beads were resuspended. Samples were returned
to room temperature before the addition of 2 µL of
proteinase K stop solution. The stop solution was warmed
for 10 min at 37 °C prior to addition. Samples were mixed
and then placed on a magnetic stand, the beads moved to
one side and the supernatant removed and transferred to
new tubes. The supernatant consisted of the methylated
gDNA fragments.
2.5.3. DNA clean up
The DNA was cleaned in order to get rid of all protein
contaminations necessary before PCR amplification. The
protocol used was the phenol/chloroform extraction and
ethanol precipitation.
2.6. Microarray and gene selection
A nonbiased genome-wide microarray promoter
methylation profiling analysis was performed in order to
obtain a list of differentially methylated genes present in
the methylation-enriched gDNA and total gDNA that had
been extracted and purified from normal primary oral
keratinocytes transduced with either EGFP or FOXM1B
and the HNSCC cell line (SCC15) as a positive control.
The genes that were most significantly differentially
methylated by FOXM1B were then identified and shortlisted. The list of candidate genes was further validated
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by using qPCR. This microarray analysis was performed
using NimbleGen 720k array chips, which cover 22,532
promoter CpG islands proximal to transcriptional start
sites. The service was provided by Roche NimbleGen, Inc.,
USA. Figure 2 illustrates the selection criteria of candidate
genes for this project. The most significantly differentially
methylated genes in control cells (NOKG) were identified.
These were then compared with gene lists of NOKF and
SSC15 cell lines. Genes that showed opposing methylation
status between NOKG and NOKF were selected and
compared with SCC15 to find the list of common genes
between NOKF and SCC15.
2.7. List of target genes and primer sequence
The 17 target genes and primers are given in Tables 3, 4,
and 5.
2.8. Real time quantitative PCR (RT-qPCR)
A LightCycler LC480 qPCR machine (Roche Diagnostics
Ltd., UK) was used for absolute gene quantification. The
SYBR Green (Roche Diagnostics) method was used. It
was confirmed that the PCR primers used only produced
a single peak. The 2 most stable reference housekeeping
genes used were YAP1 and POLR2A.
2.9. qPCR workflow
Melting peak analysis was performed to verify the
specificity of PCR primers. Ten-fold serial dilutions of
the amplified products were prepared in t-RNA solution
(Sigma). Absolute quantification for a single target gene
was achieved by creating standard curves. These were
then stored in the LC480 analysis software program for
future sample analysis. Each PCR experiment consisted of
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Figure 2. Selection of FOXM1B induced differentially methylated genes. The most
significantly differentially methylated genes in control cells (yellow) were identified.
These were then compared with a gene list of FOXM1B (blue) and SSC15 (orange) cell
lines. Genes that showed opposing methylation status between control cell line and
FOXM1B transduction cell line were selected and compared with SCC15 to find the list
of common genes between FOXM1B-treated cell lines and SCC15.

Table 3. Hypermethylated genes.
Gene

Primer sequence

110

gTET3-F
gTET3-R

aggtgcacagagtgcgagt
gcctattgctctgctcttgc

76

gTAS2R60 -F
gTAS2R60-R

ccatggatgctcttcagctc
acattctgtggttgcctatgaa

95

gFSTL3-F
gFSTL3-R

aaaagtgcccctaggttggt
cttgagtctttatttccttggtgag

93

gPDGFB-F
gPDGFB-R

tcccacctactgcactttcc
aaaggaaagcccccaaaaat

102

gGNG13-F
gGNG13-R

ggccccactcacaacatct
aggcgtggtctcacaggata

94

gNXPH2 -F
gNXPH2-R

tgagaccccatacttatcttctgg
gggcttgtttctttgtcattcta

89

gATF6B-F
gATF6B-R

tggtgagctgctgcatattt
acttcccttgtcccacctg

123

gFKBPL-F
gFKBPL-R

tgctagggcagcctcagt
ctttttccaggttcccaagg
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Size (bp)
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Table 4. Hypomethylated genes.
Gene

Primer sequence

86

gGLT8DI-F
gGLT8DI-R

gcgacgctctagcggtta
cgagcacacttgccctct

80

gSPCS1-F
gSPCS1-R

cgcgcaagtactgtcaagg
gaagtgttcgccgtcagtg

80

gFABP6-F
gFABP6-R

tgacctatgagcgcgtgagc
ttttattggtgggtttgtagctc

93

gOR3A1-F
gOR3A1-R

agctgcagtcctgcgaat
ccatagaatatggcaaccacag

93

gDNAJC17-F
gDNAJC17-R

gatgcagcaggaagaccag
aaatttattggtgacgttgaagaa

92
112
76
81
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Size (bp)

gTBC1D10B-F
gTBC1D10B-R

gctcagctggggtctctgt
cacccctgggatgacaac

gB4GALT2-F
gB4GALT2-R

ggggcttggatcagtaagtct
ctaaagcacccacacaaagat

gRAB4OB-F
gRAB4OB-R

agggaagaaaatgccaaagat
agctcttccttgacctgtcg

gBMP1-F
gBMP1-R

attcctcaccaagctcaacg
tgccagatgcagttcttgtt

Table 5. Housekeeping genes.

GCAAATTCACCAAGAAGAGACG
CACGTCGACAGGAACATCAG

YAP1-F
YAP1-R

CCCAGATGAACGTCACAGC
GATTCTCTGGTTCATGGCTGA

et

POLRA2-F
POLRA2-R

R

a standard concentration of 105 copies of target genes and
housekeeping genes in order to find out the copy number
of target genes in each unknown gDNA or cDNA sample.
The LC480 software automatically calculates the gene copy
number present in unknown samples by comparing it with
the calibrated standard (105 copies) respective to that of
previously stored standard curve for each target gene. A
Microsoft Excel spreadsheet was used for data calculation
and analysis.
3. Results
3.1. Gene expression quantification using qPCR
To quantify the exact mRNA copy number of target genes
in the FOXM1B-transduced cells and cancer cell lines,
we produced standard curves by using known DNA
concentrations (copy number). Amplification curves and
melting analyses were performed for all the target genes.
Melting analysis determines PCR product specificity by

378

showing only one peak, whereas amplification curves help
to produce standard curves to determine PCR efficiency
and curve fitting errors to allow accurate calculation of
target gene concentrations in unknown samples, based
on the Roche Light Cycler480 operating software internal
algorithm. YAP1 and POLR2A were used as housekeeping
genes, as they have been previously shown to be stably
expressed in both normal and cancer cells (4).
3.2. Target genes table
In this study 17 target genes were investigated. Table 6 is a
compilation of all the target genes. These details were taken
from the standard curve produced for each candidate gene.
3.3. Correlation between promoter methylation and gene
expression
It is known that differential promoter hypermethylation
leads to silencing of gene expression whereas
hypomethylation causes upregulation of gene expression.
In this project we used an absolute qPCR to first validate
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Table 6. Target gene standard curve metadata.
Size (bp)

Tm

Primer dimer

Error

Efficiency

1.

TET3

110

92.31

-

0.00859

1.796

2.

TAS2R60

76

82.69

-

0.00106

1.850

3.

FSTL3

95

90.27

-

0.0290

1.564

4.

PDGFB

93

82.53

-

0.0083

2.131

5.

GNG13

102

88.48

-

0.0401

1.774

6.

NXPH2

94

81.20

-

0.00860

1.797

7.

ATF6B

89

82.47

-

0.00823

1.912

8.

FKBPL

123

90.21

-

0.00512

1.906

9.

GLT8D1

86

91.10

-

0.0279

1.939

10.

SPCS1

80

88.59

-

0.0214

2.050

11.

FABP6

80

88.50

-

0.00818

1.938

12.

OR3A1

93

85.85

-

0.00886

1.714

13.

DNAJ17

93

87.00

-

0.0950

1.652

14.

TBC1D10B

92

87.00

-

0.00835

1.992

15.

BMP1

81

91.20

-

0.0413

2.230

16.

B4GALT2

112

85.60

-

0.0277

1.952

76

81.60

-

0.0137

1.889

17.

RAB40B
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the differential methylation of genes in methylated gDNA
collected from our control primary normal human
oral keratinocytes, expressing either EGFP (NOKG) or
FOXM1 (NOKF) SCC15 cell lines, and in methylated
gDNA and cDNA collected from tissue biopsy of 3 pairs
of normal margin and oral SCC cells. The absolute qPCR
measured and compared the relative methylation and
gene expression of the 17 candidate FOXM1B-induced
differentially methylated genes that were identified from
the microarray study. These genes showed the parallel
deferential gene expression in both cultured cells and in
patient tumor tissues. According to our hypothesis, if the
shortlisted 17 target genes were involved in oncogenesis,
then their promoter methylation status would modify
the gene expression in the cancer tissues as well. In order
to support our hypothesis we performed absolute qPCR
to measure the gene expression of these candidate genes
in 3 pairs of normal margin and HNSCC biopsy tissues.
Once their gene expression levels were obtained we next
correlated them with the promoter DNA methylation
status of these genes in FOXM1B-transduced cells.
3.4. DNA methylation vs. mRNA expression in NOKF
To validate if the candidate genes were indeed differentially
methylated in FOXM1-transduced cells (NOKF),

methylation (using gDNA) and gene expression (cDNA)
were quantified for each gene in NOKG and NOKF.
Differential methylation and gene expression were then
calculated for each gene as a ratio of NOKF:NOKG and
plotted as a correlation chart between gene expression
and relative methylation. Figure 3 shows that there is an
inverse correlation between promoter methylations and
their respective gene expressions in FOXM1B-transduced
cells, with a regression coefficient R2 value of 0.564. Each
data point with an error bar represents the mean ± SEM of
3 NOKF samples. A positive control gene, CDKN2A/p16,
known to be hypermethylated by FOXM1B, was included
in this study. This negative correlation is in agreement with
our hypothesis. According to this graph, the methylation
status of target genes from the microarray analysis is
consistent with the qPCR results.
3.5. DNA methylation vs mRNA expression in SCC cell
lines
Using the same validation strategy as above, the candidate
genes were subsequently validated in SCC15 cell lines.
Similarly, Figure 4 shows a negative relation between the
promoter DNA methylation and relative mRNA expression
in the SCC15 cell line with a regression coefficient R2 of
0.502.

379

ra
ct
ed

UMAIR et al. / Turk J Med Sci

Figure 3. Inverse correlation between FOXM1B-induced
promoter methylation in NOK and relative mRNA expression in
NOKF. Green dots represent hypomethylated genes and red dots
hypermethylated genes.

Figure 4. Promoter DNA methylation vs. relative mRNA
expression in SCC15.
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3.6. DNA methylation in NOKF vs. relative mRNA
expression in HNSCC cell lines
We next investigated whether the candidate gene
expression pattern was a common phenomenon across
different HNSCC cell lines. There were 8 samples used
(SCC15, 5PT, VB6, SqCC/Y1, SVpgC2a, SVFN4, SVFN5,
and SVFN10 ). cDNAs were prepared from these 8
independent HNSCC cell lines and then compared with
DNA methylation status for each candidate gene. Figure
5 shows the inverse correlation between the promoter
methylation status in FOXM1B-induced cells, NOKF,
and the corresponding gene expression in HNSCC cell
lines. The regression coefficient R2 was 0.849. This graph
indicates that the candidate genes selected from FOXM1Binduced cells behaved the same in HNSCC cell lines.

3.7. Correlation between NOKF and tissue biopsies
Having established that the candidate differentially
methylated genes showed inverse gene expression patterns
in HNSCC cell lines, we next investigated if this trend
persisted in in vivo HNSCC tumor biopsy tissues as well.
First, the relative methylation status of each gene was
compared between gDNA extracted from NOKF and
HNSCC tissues. Three pairs of tissue biopsy samples were
used. In Figure 6A there is a positive correlation between
promoter methylation of NOKF and HNSCC tissue
biopsies’ gDNA, with a correlation coefficient of R2 =
0.637. This indicates that the methylation signature found
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Figure 5. Correlation between FOXM1B-induced promoter
methylation in NOK and relative mRNA expression in HNSCC
cell lines (n = 8).

in NOKF appears to be similar to that found in HNSCC
tumor tissues.
To further validate that the differential methylation
signature indeed resulted in inverse gene expression in the
tumor tissues, the gene expressions of each of the candidate
genes were quantified and compared between the 3 pairs
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Figure 6. A) Correlation between the relative promoter methylation in NOKF and HNSCC biopsy tumor tissues. B)
Promoter DNA methylation in NOKF cells and its corresponding mRNA expression in HNSCC biopsies.
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of normal margin and HNSCC tumor tissues. In Figure
6B an inverse correlation is shown between promoter
methylation in NOKF and its corresponding mRNA
expression in HNSCC tissues. The correlation coefficient
R2 is 0.921. This graph provides data that seem to be in
agreement with our hypothesis that FOXM1 induces a
cancer-like methylation signature. As stated previously,
if the candidate genes were involved in oncogenesis, we
hypothesized that their promoter methylation status
would change the mRNA expression in tumor tissues.
3.8. Correlation between DNA methylation and relative
mRNA expression in individual patient samples
Although the candidate genes showed differential gene
expression in the HNSCC tumor samples, the methylation
statuses of these genes in the tumor samples were not
known. In order to investigate this, gDNA from the same
3 pairs of normal margin and tumor tissues were analyzed
for differential methylation. Figures 7A–7C show 3 patient
samples, A, B, and C. These graphs illustrate the inverse
correlation of individual patient between promoter DNA
methylation and relative mRNA expression.
Figure 7D shows the average association between
the methylation status and the corresponding cDNA
expression in all 3 patient samples. In the graph of patient
A, all genes other than OR3A1 behaved as expected,
hence giving an inverse relation value for R2 of 0.972. The
genes that were hypomethylated were highly expressed,

such as, for example SPCS1 and GALT8D1, whereas the
hypermethylated genes showed low levels of expression of
their respective genes, for example PDGFB and TET3.
The graph for patient B also shows a negative relation,
with a regression coefficient R2 value of 0.577. FKBPL showed
an opposing DNA methylation status, which related well
to its mRNA expression. Other hypermethylated genes,
such as TAS2R60, PDGFB, FSTL3, and UTR-p16, showed
downregulation of respective gene expression, whereas the
hypomethylated genes such as SPCS1, OR3A1, GLT8D1,
and FABP6 showed corresponding gene upregulation.
For patient C, an inverse relation was seen with
regression coefficient R2 of 0.760. In this graph the
methylation statuses of a few genes were not consistent with
the microarray results, as these genes showed opposing
methylation statuses, for example FSTL3, PDGFB,
TAS2R60, and OR3A1. Nevertheless, genes FSTL3, PDGFB,
and TAS2R60 showed DNA hypomethylation, but these 3
genes correlated well to their respective gene expression,
whereas OR3A1 showed DNA hypermethylation and
corresponding gene expression downregulation.
In Figure 7D, all 3 patients’ data were averaged to
obtain the combined result of the relationship between
the promoter DNA methylation and respective mRNA
expression levels. As expected, a negative correlation
between methylation and gene expression was obtained,
having a regression coefficient of 0.954.
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Figure 7. Correlation between DNA methylation and relative mRNA expression in individual patient samples (A–C) and
averaged data for 3 patients (D).

4. Discussion
FOXM1, an important transcription factor for the
regulation of cell cycle, cell division, genomic stability,
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aging, and development, has been found to be
ubiquitously upregulated in many human cancers. It
is known that FOXM1 expression is upregulated early
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(33), of which CDK4 has a role, and p16 has a regulatory
function over CDK4. Silencing of the gene p16 has been
associated with numerous cancer cell lines. It is found to
be inactive in HNSCC and is associated with advanced
stages of this type of cancer (34). The silencing of p16 as
a result of induced hypermethylation by FOXM1 may
promote cancer development and progression.
Next, the candidate genes were subsequently validated
in the SCC15 cell line using the same validation strategy
as above. An inverse negative correlation between the
promoter DNA methylation and relative mRNA expression
in the SCC15 cell line, with a regression coefficient R2
of 0.502 (about 50%) was obtained. Four genes, PDGFB,
FKBPL, OR3A1, and SPCS1, showed opposing methylation
status. However, the mRNA expression of these 4 genes
correlates well with their respective promoter methylation
status. For example, SPCS1 and OR3A1 showed
hypermethylation with corresponding downregulation of
gene expression. Similarly, PDGFB and FKBPL showed
hypomethylation and upregulation of the relevant gene
expression. The FKBPL gene encodes a protein that plays
a role in immunoregulation and basic cellular processes
involving protein trafficking and folding. It is thought to
have a role in induced radio resistance and also appears
to have involvement in cell cycle (Gene ID 63943, NCBI
2011). The other PDGFB gene encodes for a protein that
is a member of the platelet-derived growth factor family.
Mutations in this gene are associated with meningioma.
Reciprocal translocations between chromosomes 22 and 7,
at sites where this gene and that for COLIAI are located,
are associated with a particular type of skin tumor called
dermatofibrosarcoma (Gene ID 5155, NCBI 2011).
To confirm whether the candidate gene expression
pattern was a common phenomenon across different
HNSCC cell lines, gene expression was measured in 8
independent HNSCC cell lines for correlation with DNA
methylation status for each candidate gene. The results
indicated that the candidate genes selected from FOXM1Binduced cells showed a similar inverse correlation between
methylation and gene expression. A coefficient of R2 =
0.845 (about 85%) was obtained. This was true except
for 2 genes, GNG13 and ATF6B, which showed promoter
hypomethylation in NOKF and low levels of their
corresponding gene expression in HNSCC cell lines. Their
methylation status did not match their respective mRNA
expression levels. The candidate differentially methylated
genes showed inverse gene expression pattern in HNSCC
cell lines. In order to investigate if the same trend persisted
in HNSCC tumor biopsy tissues we compared the relative
methylation status of each gene between gDNA extracted
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during HNSCC carcinogenesis (4). The understanding of
the early mechanism of cancer initiation can help us find
effective interventions for cancer prevention and cure.
FOXM1’s role in cancer initiation by perturbing stem
cell renewal has been recently established (5). Epigenetic
modifications like DNA methylation and demethylation
are also known to occur early during cancer (6). It is
hence important to know whether FOXM1 has a role in
epigenetic modification that initiates cancer formation.
We hypothesize that upregulation of FOXM1 induces
cancer-inducing epigenetic modifications such as DNA
methylation and demethylation. In order to support our
hypothesis we analyzed a list of differentially methylated
genes that had been shortlisted after performing a genomewide microarray promoter DNA methylation study. The
promoter DNA methylation pattern and corresponding
mRNA expression of each candidate gene is measured
in normal primary oral keratinocytes with increased
FOXM1expression by using real-time absolute qPCR and
is then compared to HNSCC cell lines, HNSCC biopsy
cDNA samples, and a normal control.
An absolute qPCR was used to obtain a standard curve
for each candidate gene so that accurate levels of promoter
DNA methylation and the respective mRNA expression
could be measured. First, to validate that the target
genes were indeed differentially methylated in FOXM1transduced cells, the promoter methylation and relative
gene expression were quantified for each gene in control
cells (NOKG) and NOKF. The data obtained showed that
the microarray analysis was mostly consistent with the
qPCR results, whereby the methylation status of each gene
was inversely correlated with gene expression. An inverse
relation was obtained with a correlation coefficient of R2
= 0.564 (about 56%). Two genes, ATF6B and GNG13, that
were expected to be hypermethylated did not exhibit the
strong status that was seen in microarray gene expression
for FOXM1 and SCC15, but nevertheless their respective
mRNA expressions were consistent with their DNA
methylation status. This highlights the importance of
validating microarray results using qPCR. A positive
control gene, p16, which is known to be a tumor-suppressor
gene, was included in this study. It was shown from the
results that this gene was hypermethylated in NOKF and
in the majority of HNSCC cell lines and tumor tissues
and, correspondingly, its mRNA expression levels were
suppressed. The p16 gene has a regulatory role in the cell
cycle. It stabilizes the tumor suppressor gene p53, which
controls apoptosis (32). Mutation of this gene increases
the risk of developing cancer. It can cause downregulation
of genes and impairment of the retinoblastoma pathway

383

UMAIR et al. / Turk J Med Sci
DNA methylation has emerged as a highly promising
biomarker and is being actively studied in multiple
cancers, and a large number of potential biomarkers have
been identified. In prostate cancer the hypermethylation
of the glutathione-S-transferase pi gene has emerged as
a good diagnostic marker (37). This project can help us
find good biomarkers for the early detection of HNSCC. In
this study most of the candidate genes showed differential
methylation status in both FOXM1-transduced cells and
in HNSCC when compared to normal control cells. These
genes may have a clinical potential for early diagnosis of
cancer as well as prognosis and therapeutic treatments. By
detecting the methylation status of various genes we can
measure the level of genomic instability in cells, which
may guide us into cancer prognostics. It is well known
that tumor suppressor genes are hypermethylated and
hence silenced in cancer, and the use of demethylating
drugs, which could interact with enzymes such as DNA
methyltransferase, can play a fundamental role in the
therapeutic treatment of cancer. Procaine is one such drug
that has been found to have growth inhibitory effects on
human cancer cells. In the future we may be able to prevent
cancer by arresting the reversible epigenetic modifications
before irreversible mutation takes place.
In summary, this study shows that upregulation
of FOXM1 leads to cancer-like epigenetic alterations
in normal primary human oral keratinocytes. The
differentially methylated genes selected from microarray
analysis were validated using qPCR. Genes with promoter
hypermethylation showed corresponding low levels of
mRNA expression and hypomethylated genes showed
elevated levels of relative gene expression. The same
pattern was observed in HNSCC cell lines as well as in
HNSCC tumor biopsy samples. We need further studies
to confirm the mechanism of epigenetic modifications and
the role of each gene in cancer initiation. Future proposed
experiments include the following aims:
1. To investigate the mechanism by which FOXM1
causes differential promoter methylation of candidate
genes.
2. To investigate the role of the differentially methylated
genes in cancer initiation and progression.
3. To investigate whether the genes identified in this
study could be used in clinical practice as early detection
biomarkers and for cancer prognostics. Further clinical
samples validation studies would be required to establish
their clinical use.
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from NOKF and HNSCC tissue. A positive correlation
with a coefficient of R2 = 0.637 (about 64%) was obtained.
OR3A1 showed promoter hypermethylation status in
NOKF with a corresponding low expression of mRNA,
whereas hypomethylation in HNSCC was consistent with
gene expression. The data indicated that the methylation
signature found in NOKF appear to be similar to that found
in HNSCC tumor tissues. Next, the gene expressions of
each of the candidate genes were quantified and compared
between the 3 pairs of normal margin and HNSCC
tumor tissues to validate that the differential methylation
signature indeed resulted in inverse gene expression in the
tumor tissues. There was an inverse correlation between
promoter methylation in NOKF and its corresponding
mRNA expression in HNSCC tissues, with a correlation
coefficient of R2 = 0.921 (about 92%). This shows that
FOXM1 induces a cancer-like methylation signature.
To investigate the level of heterogeneity within each
patient, an individual patient’s methylation status and gene
expression was studied for each candidate gene. In patient
A, an inverse relation of R2 value of 0.972 was obtained.
The OR3A1 gene showed hypermethylation, which was
the same as in NOKF, but it did not correspond with
its respective gene expression. In patient B, a regression
coefficient R2 value of 0.577 was obtained. FKBPL showed
opposing DNA methylation status, but it related well to its
mRNA expression. In patient C, the methylation statuses
of a few genes were not consistent with the microarray
results. FSTL3, PDGFB, TAS2R60, and OR3A1 genes
showed opposing methylation status but correlated
well with their respective gene expression. These results
demonstrated an interpatient heterogeneity with certain
candidate genes. Nevertheless, the overall trends of
methylation and gene expression were consistent with our
hypothesis that FOXM1 induced a cancer-like methylation
pattern that is found in tumor biopsy tissues. In the end,
we averaged the data of the 3 patients to obtain a combined
result of the relationship between the promoter DNA
methylation and respective mRNA expression levels. As
expected, a negative correlation between methylation
and gene expression was obtained, having a regression
coefficient of 0.954 (about 95%).
Modifications in genomic methylation status may be an
enhancing factor in the oncogenesis process, and evidence
shows that global DNA hypomethylation might contribute
to genomic instability and increased mutation rate (35).
Wide-spread global hypomethylation is accompanied
with hypermethylation in a few genes and an increase in
DNMT1, an enzyme responsible for regulating promoter
methylation (36).
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